Good news for cannabis and hemp advocates alike. On July 26, 2018, United Kingdom Home Secretary Sajid Javid announced that he would reschedule cannabis from a Schedule I substance to a Schedule II substance. The announcement has sweeping implications for GW Pharmaceuticals, which holds an exclusive license in the UK to produce cannabinoid-based medicines. Most recently, the company earned approval from the US Food and Drug Administration for its CBD-based drug Epidiolex, which is expected to be sold in the US later year (following DEA scheduling) and the in the UK in 2019. Rescheduling medical cannabis in the UK may also stand to benefit companies developing pharmaceuticals based on hemp, which are often confused with cannabis.
To read more, please visit the original post at CannabisFN.